AbbVie, with a market cap of over $300 billion, shows strong cash flow potential despite patent expirations, making it a ...

NORTH CHICAGO, Ill. and SHANGHAI, Jan. 13, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) today announced an option to ...

The stock's rise snapped a four-day losing streak.

Johnson & Johnson (J&J) has agreed to pay $132 per share to acquire Intra-Cellular Therapies Inc. in a deal valued at about $14.6 billion, taking ownership of Caplyta (lumateperone), a once-daily oral ...

In its latest attempt to bulk up its cancer drug portfolio, AbbVie has signed a new licensing agreement with China-based Simcere Zaiming to develop a treatment for myeloma, a type of blood cancer, in ...

AbbVie Inc (ABBV) stock saw a decline, ending the day at $175.17 which represents a decrease of $-3.33 or -1.87% from the prior close of $178.5. The stock opened at $176.86 and touched a low of ...

Simcere Pharmaceutical said on Monday its unit had granted U.S. drugmaker AbbVie the option to license its new blood cancer ...

Emraclidine was the centerpiece of AbbVie’s $8.7 billion acquisition of Cerevel in December 2023 but failed two mid-stage ...

Czech National Bank increased its stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 6.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The ...

Under the terms of the agreement, AbCellera will lead discovery activities and AbbVie has the right to develop and commercialize therapeutic antibodies resulting from the collaboration. AbCellera will ...